Product Pipeline
| Candidate & Indication | Development Stage | ||||
|---|---|---|---|---|---|
| R & D | Preclinical | Phase 1 | Phase 2 | Phase 3 | |
| Iomab-B (CD45) (apamistamab-I-131) BMT conditioning1 |
R & D Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase complete
|
Phase 3 Phase in progress
|
| Iomab-ACT (CD45) (apamistamab-I-131) GeneTx and Cell therapy conditioning |
R & D Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
| Actimab-A (CD33) and CLAG-M Relapsed/Refractory AML |
R & D Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
| Actimab-A (CD33) and Venetoclax Relapsed/Refractory AML |
R & D Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
|
Actimab-A CD33
CompletedAML Newly diagnosed patients with AML over age 60 |
R & D Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
| Actimab-A (CD33) and Venetoclax with HMA PlannedRelapsed/Refractory AML |
R & D Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
|
Actimab-M CD33
Multiple Myeloma penta refractory patients age 18 and above |
R & D Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
| Actimab-MDS CD33 PlannedMyelodysplastic Syndrome (MDS)Myeloablation prior to BMT for high-risk MDS patients |
R & D Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
| AWE Technology Platform Actinium-225 conjugated to daratumumabCD38 targeting agent for multiple myeloma |
R & D Phase complete
|
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
| Actimab-C Colon Cancer |
R & D Phase complete
|
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
| Actimab-P Prostate Cancer |
R & D Phase complete
|
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
| Actimab-Br Brain Cancer |
R & D Phase complete
|
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
- BMT or HSCT (Hematopoietic Stem Cell Transplantation) is a procedure in which cells capable of reconstituting normal bone marrow function are transplanted to a patient.